Department of Endoscopy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China.
Respiration. 2017;94(3):293-298. doi: 10.1159/000477764. Epub 2017 Jul 6.
We have recently developed a flexible catheter electrode used for bronchoscopic radiofrequency ablation (RFA). Two patients with nonsurgical stage IA peripheral lung cancer and 1 with lung metastasis underwent treatment with flexible catheter RFA utilizing navigation bronchoscopy. Chest computed tomography (CT) and positron emission tomography/CT (PET/CT) were performed before and after RFA to assess the ablation response of the patients. One patient's tumor had no prior PET uptake and therefore no follow-up PET was obtained. The first and the third patient obtained partial response to RFA, and the second patient obtained complete response 3 months after RFA. The first patient developed progressive disease 6 months after RFA. The second and the third patient achieved one-year progression-free survival. No significant complications occurred in the 3 patients. Navigation bronchoscopy-guided RFA is a safe and feasible procedure for poor surgical candidates with stage IA lung cancer or lung metastasis.
我们最近开发了一种用于支气管镜射频消融(RFA)的柔性导管电极。两名非手术治疗的 I 期周围型肺癌患者和 1 名肺癌转移患者接受了导航支气管镜下柔性导管 RFA 治疗。在 RFA 前后进行了胸部计算机断层扫描(CT)和正电子发射断层扫描/CT(PET/CT)检查,以评估患者的消融反应。一名患者的肿瘤之前没有摄取 PET,因此没有进行后续的 PET 检查。第一和第三例患者对 RFA 有部分反应,第二例患者在 RFA 后 3 个月获得完全反应。第一例患者在 RFA 后 6 个月出现进行性疾病。第二和第三例患者实现了无进展生存 1 年。这 3 例患者均未发生明显并发症。导航支气管镜引导下 RFA 是一种安全可行的方法,适用于不能手术的 I 期肺癌或肺癌转移患者。